SDC1 and Miyoshi myopathy: While no clinical trials have yet been reported for CD138 CAR-NK cells, the robust preclinical data underscore their translational potential as part of the next generation of allogeneic, “off-the-shelf” immunotherapies for relapsed or refractory MM.